Phio Pharmaceuticals Corp.
PHIO
$2.36
-$0.04-1.67%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -98.48% | 52.95% | |||
| Gross Profit | 98.48% | -52.95% | |||
| SG&A Expenses | 43.11% | -27.17% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.83% | 5.28% | |||
| Operating Income | -11.83% | -5.28% | |||
| Income Before Tax | -8.79% | -6.69% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -8.79% | -6.69% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -8.79% | -6.69% | |||
| EBIT | -11.83% | -5.28% | |||
| EBITDA | -11.80% | -5.28% | |||
| EPS Basic | 71.28% | 7.11% | |||
| Normalized Basic EPS | 71.27% | 7.12% | |||
| EPS Diluted | 71.28% | 7.11% | |||
| Normalized Diluted EPS | 71.27% | 7.12% | |||
| Average Basic Shares Outstanding | 278.76% | 14.87% | |||
| Average Diluted Shares Outstanding | 278.76% | 14.87% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||